EN DE
Watch AnaptysBio Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

AnaptysBio Inc (ANAB) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of AnaptysBio Inc stock $67.19, price $46.45, upside +44.7%, quality 68 out of 100. Rating: undervalued. Calculated from audited financials with 13 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

AI AnaptysBio Inc logo Some data Nov 6, 2026

AnaptysBio Inc

ANAB · US
Meets all rules: undervalued, solid quality, uptrend

The stock costs 31% less than our calculation considers fair.

Fair value $67.19 · Undervalued (31%)
Quality 68/100
Low debt
Generates free cash flow
Revenue last quarter +24% vs. a year ago.
Mixed Growth (revenue 5y +25.6 %/yr in USD)
Mixed vs. peers (7/12)
Insiders sold $249,372 (6M)
Some data
Loss-making · -5.6% net margin (FY2025)
Narrow moat 38/100 · thin data
Watch AnaptysBio Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$69.81 $8.25 Fair Value $67.19 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.

How to read this chart

60‑month range $8.25 – $69.81 · fair‑value band $39.57 – $81.64 · the $46.45 price screens below the $67.19 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 6, 2026.

Follow AnaptysBio in your weekly email

Every Wednesday you see whether AnaptysBio is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States.

Show moreShow less

The company's products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial for celiac disease and eosinophilic esophagitis; ANB101, a BDCA2 modulator antibody which is in Phase 1a trial that specifically targets plasmacytoid dendritic cells and inhibits interferon secretion and modulates antigen presentation; dostarlimab, a PD-1 antagonist for various solid tumor indications; and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.

It focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has collaborations agreement with GSK and Vanda. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006.

AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

Stock analysis

AnaptysBio Inc (ANAB) currently trades at $46.45, while our model-based Fair Value estimate is $67.19, implying the stock looks roughly 31% undervalued today.

Show more

Valuation

Bull case: the Growth DCF group reads highest at a median of $71.36 per share, and 7 of the 13 models we run sit above the $46.45 price.

Bear case: the Earnings-Based group reads lowest at $22.62, and 6 of the 13 models stay below the price. Data coverage for this calculation is medium.

Scenario range: $39.57 (bear) to $81.64 (bull), the price of $46.45 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 68/100 (solid quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

AnaptysBio Inc reported revenue of $235M in FY2025 versus $63.2M in FY2021, a compound +38.8%/yr. Reported net income was −$13.2M in FY2025.

Key figures

Market cap $1.3B Small · P/S ratio 12.8 · EPS (TTM) $−0.9600 · Net margin −5.6% · Return on equity −115% · Return on assets (EBIT) −14.9% (5-year average) · Operating margin 53.4% · Revenue (TTM) $106M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).

What moves the price

The share trades about 33% below its 52-week high and 111% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at 45%, ANAB screens cheaper than that median.

Fair Value models

Bear $39.57 Fair Value $67.19 Bull $81.64
Price $46.45 · Upside +44.7%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF $54.93 $79.36 $154.63 75
EPV $20.68 $22.62 $24.28 74
Growth DCF $52.04 $89.86 $150.30 74
All 13 models by family
DCF Models
FCF DCF $54.93 $79.36 $154.63 75
5Y Revenue Exit $33.11 $47.16 $76.20 69
5Y EBITDA Exit $34.60 $50.18 $80.52 72
10Y Revenue Exit $39.57 $67.19 $81.64 65
10Y EBITDA Exit $41.24 $70.28 $117.22 64
Earnings-Based
EPV $20.68 $22.62 $24.28 74
Multiples
EV/EBIT $27.92 $34.73 $41.54 66
EV/EBITDA $25.17 $31.06 $36.95 67
EV/Revenue $22.08 $28.32 $34.57 54
Asset-Based
NCAV (Graham) $0.5100 $0.7700 $0.9600 55
Growth DCF
Growth DCF $52.04 $89.86 $150.30 74
Rev-Margin DCF $35.46 $52.86 $89.59 69
Economic Profit
ROIC Compounder $20.68 $22.62 $24.28 70

Open the full fair value analysis →

Quality Score breakdown

Overall quality 68/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 30
How much profit the company makes from its sales and capital
Quality Growth 100
Are margins and returns getting better?
Cashflow 61
Do the profits arrive as real cash?
Financial strength 46
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 43
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 76
Distance to the 52-week high, does not count
New shares 81
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, one officer or director sold shares worth $249,372 and none bought.

  • SaleHollings RentonDirector5,000 shares at $49.87$249,372Oct 1, 202610b5-1 plan
  • SaleJohn P. SchmidDirector20,645 shares at $56.11$1.2MMar 30, 2026
  • SaleDaniel FagaPresident, CEO, Director4× since Jan 5, 2026: 56,471 shares, avg. $49.67$2.8MMar 27, 2026
  • SaleEric J LoumeauCHIEF LEGAL OFFICER6× since Dec 16, 2025: 57,473 shares, avg. $47.75$2.7MFeb 11, 2026
  • SaleMagda MarquetDirector11,000 shares at $48.23$530,568Jan 15, 2026
  • SaleDennis MulroyCHIEF FINANCIAL OFFICER5× since Dec 16, 2025: 33,511 shares, avg. $46.24$1.5MJan 8, 2026
  • SalePaul F. LizzulChief Medical Officer4× since Dec 22, 2025: 11,604 shares, avg. $44.94$521,526Jan 8, 2026
  • SaleJ. Anthony WareDirector3,900 shares at $49.58$193,362Dec 23, 2025

Plus 5 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 6, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 86/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+157.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+183.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+25.6%
Start year 2020 (pandemic). Over 10 years: +29.6% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+36.8%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−31.8% (2020) → 20.4% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Growth Forecast

A lot of optimism in the price
The price assumes about as much growth as the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+28.1%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+20.9%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +25.2% a year for the price and +18.1% for the forecasts.
Forecast 2026 (sales)−56.9%
Forecast 2027 (sales)+69.4%
Projected 2028 (sales)+61.0%
Projected 2029 (sales)+52.6%
Projected 2030 (sales)+44.1%

Watch ANAB, get fair value alerts →

Compare AnaptysBio Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks

Beats the industry median on 7/11 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 68 · Top 25%
Fair Value upside +44.7% · Top 25%
Profitability
Return on assets −3.6% · Above median
Net margin (12 months) −5.6% · Below median
Operating margin (12 months) 53.4% · Top 25%
Growth and dividend
Revenue growth (quarter YoY) 23.5% · Top 25%
Balance sheet
Debt / equity 0.02× · Below median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 35.82× · Priciest 25%
P/S (12 months) 12.56× · Priciest 25%
Price / free cash flow (fiscal year) 68.0× · Priciest 25%
EV/EBITDA 16.7× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)93 · sector 0
FUTURE (revenue growth)100 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)99 · sector 97
DIVIDEND (yield)0 · sector 22

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Incyte Corporation INCY $119.65 $199.23 +67% vs ANAB
Regeneron Pharmaceuticals, Inc REGN $904.35 $1,275 +41% vs ANAB
Genmab A/S GMAB kr 3,527 kr 3,999 +13% vs ANAB
Samsung Biologics Co 207940 1,516,000 KRW 1,667,600 KRW +10% vs ANAB
WuXi Biologics (Cayman) Inc 2269 HK$47.62 HK$52.38 +10% vs ANAB
Vertex Pharmaceuticals Incorporated VRTX $547.09 $596.75 +9% vs ANAB
argenx SE ARGX $927.21 $908.40 −2% vs ANAB
CSL Limited CSL A$202.04 A$183.04 −9% vs ANAB
Celltrion, Inc 068270 211,000 KRW 74,945 KRW −64% vs ANAB
Royalty Pharma plc RPRX $67.30 $19.01 −72% vs ANAB

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Evidence & backtest34 years, failed companies included Financial calculatorsDCF, Graham, PEG and more
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

AnaptysBio Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "AnaptysBio Inc Fair Value". https://www.fairvalue-calculator.com/stock/ANAB

Frequently asked questions

Is AnaptysBio Inc (ANAB) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of $67.19 versus a price of $46.45, about +45% upside (undervalued).
What is the fair value of ANAB?
Our model-based fair value for AnaptysBio Inc is $67.19 (as of Nov 6, 2026), built from audited fundamentals. The current price: $46.45.
What is the quality score of ANAB?
AnaptysBio Inc has a Quality Score of 68/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for AnaptysBio Inc (ANAB)?
Our model-based price target is the fair value of $67.19 (as of Nov 6, 2026) from 13 valuation models. Cautious scenario $39.57, optimistic scenario $81.64. It is a calculation from audited fundamentals, not an analyst target.
What is the AnaptysBio Inc stock forecast for 2026?
Our models put fair value at $67.19, about +45% upside versus a price of $46.45 (undervalued). Cautious scenario $39.57, optimistic scenario $81.64. The calculation is refreshed regularly with new filings.
What is the revenue of AnaptysBio Inc (ANAB)?
AnaptysBio Inc reported trailing-twelve-month revenue of about $106M (latest available figure, as of Nov 6, 2026).
What growth is priced into AnaptysBio Inc (ANAB)?
For today's price to be fair in a discounted-cash-flow model, AnaptysBio Inc would have to grow free cash flow by +28.1 % per year for five years (discount rate 9.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +25.6 % per year. As of Nov 6, 2026.
What discount rate (WACC) does the fair value of ANAB use?
Our models discount AnaptysBio Inc at 9.8 %: a base by market capitalisation (small), damped by beta 0.37, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For AnaptysBio Inc that is +28.1 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (9.8 %) and the same formula as our fair value.
How much growth has AnaptysBio Inc (ANAB) delivered so far?
Over the past 5 years revenue at AnaptysBio Inc grew +25.6 % a year. The price currently implies free-cash-flow growth of +28.1 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of AnaptysBio Inc (ANAB) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into AnaptysBio Inc (+28.1 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of AnaptysBio Inc (ANAB)?
The free-cash-flow yield on the price is 1.47 %: that much free cash flow AnaptysBio Inc produces per unit of market value. When it exceeds the discount rate of our models (9.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of AnaptysBio Inc (ANAB)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For AnaptysBio Inc it is $67.19 per share (as of Nov 6, 2026), against a price of $46.45. It is the blended result of 13 valuation models in 6 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit).
Is AnaptysBio Inc stock overvalued or undervalued in 2026?
As of Nov 6, 2026, ANAB trades below its calculated fair value: price $46.45, fair value $67.19, a gap of about +45% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ANAB?
No. The price is what the market pays today ($46.45); the fair value is what the company's own numbers justify ($67.19). For AnaptysBio Inc the two are $20.74 per share apart. That gap is exactly why we show both numbers side by side.
How much is AnaptysBio Inc worth?
The market values AnaptysBio Inc at about $1.3B (market capitalisation, as of Nov 6, 2026). Per share that is $46.45; our models calculate a fair value of $67.19 per share.
What do the bullish and bearish scenarios say about ANAB?
Our models span a range for AnaptysBio Inc: cautious scenario $39.57, base $67.19, optimistic $81.64 per share (as of Nov 6, 2026, price $46.45). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of AnaptysBio Inc (ANAB)?
Balance-sheet figures for AnaptysBio Inc (as of Nov 6, 2026): return on equity −114.6%, debt of 0.02 per unit of equity. They feed the Quality Score of 68/100, which measures business quality independently of the share price.
How far is ANAB from its 52-week high?
AnaptysBio Inc trades at $46.45, about 33% below its 52-week high of $69.81 and 111% above the low of $22.06 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $67.19 is for.
Which stocks are comparable to AnaptysBio Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is AnaptysBio Inc stock attractive at the current price?
The data as of Nov 6, 2026: price $46.45, calculated fair value $67.19 (+45%), Quality Score 68/100, from 13 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ANAB calculated?
We run AnaptysBio Inc through 13 models from 6 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit. Every model gets the same audited fundamentals; the fair value of $67.19 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. AnaptysBio Inc currently trades 31% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of AnaptysBio Inc (ANAB)?
The closing price on Nov 6, 2026 was $46.45. Our model-based fair value is $67.19, about +45% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with AnaptysBio Inc right now?
Solid quality (68/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range ($39.57 to $81.64) leaves room in how you read the outcome.

Key figures of AnaptysBio Inc

How large is the market capitalisation of AnaptysBio Inc (ANAB)?
The market capitalisation of AnaptysBio Inc is $1.3B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of AnaptysBio Inc (ANAB)?
The price-to-sales ratio of AnaptysBio Inc is 12.8 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of AnaptysBio Inc (ANAB)?
Earnings per share at AnaptysBio Inc are $−0.9600. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of AnaptysBio Inc (ANAB)?
The net margin of AnaptysBio Inc is −5.6% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of AnaptysBio Inc (ANAB)?
The return on equity (ROE) of AnaptysBio Inc is −115% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of AnaptysBio Inc (ANAB)?
On an EBIT basis the return on assets of AnaptysBio Inc is −14.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of AnaptysBio Inc (ANAB)?
The operating margin of AnaptysBio Inc is 53.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at AnaptysBio Inc (ANAB)?
Revenue at AnaptysBio Inc is growing +23.5% versus a year earlier (3y avg +184%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much net cash does AnaptysBio Inc (ANAB) hold?
AnaptysBio Inc holds more cash than debt, $224M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch AnaptysBio Inc in the live analysis

One click puts AnaptysBio Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.